Literature DB >> 8118380

Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer.

Z F Zhang1, A S Sarkis, C Cordon-Cardo, G Dalbagni, J Melamed, A Aprikian, D Pollack, J Sheinfeld, H W Herr, W R Fair.   

Abstract

Epidemiological studies show an increased risk of bladder cancer associated with tobacco smoking and occupational exposures. Certain carcinogens in tobacco and occupational exposures cause DNA damage and may produce specific mutations. TP53 is considered a common target for carcinogenic agents, and mutations of this gene are reported to be the most frequent nuclear abnormalities in human cancer. In order to investigate the relationship between tobacco smoking, occupations, and altered patterns of p53 expression, we have analyzed a group of 109 incident patients with superficial transitional cell carcinoma of the bladder. We assessed p53 nuclear overexpression by the use of anti-p53 antibody PAb1801 and immunohistochemistry, and identified 45 of 109 patients (41%) displaying p53-positive phenotype. We observed a significant association between the number of cigarettes smoked per day and p53 nuclear overexpression (p = 0.02). The odds ratios were 2.3 for those smoking 1-2 packs per day and 8.4 for smoking more than 2 packs per day. Similar estimates were obtained after controlling for age, sex, and race. Elevated odds ratios were also observed for dye-/ink-related (odds ratio = 2.0; 95% CI, 0.4-9.4) and cooking-related occupations (1.8, 0.6-5.0), although those were not statistically significant. These data support the hypothesis that certain carcinogens derived from cigarette smoking and occupations may induce TP53 mutations, which in turn are involved in early steps of bladder carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118380

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  8 in total

1.  Bladder cancer mortality in the Epirus district population (Greece).

Authors:  D Baltogiannis; A Tasos; G Voutsinas; H Dauaher; P Chambilomatis; X Giannakopoulos
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.

Authors:  Arshad Rahmani; Mohammad Alzohairy; Habeeb Khadri; Ashish K Mandal; Moshahid A Rizvi
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

3.  Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.

Authors:  Petra Lenz; Ruth Pfeiffer; Dalsu Baris; Alan R Schned; Mikiko Takikita; M Cristina Poscablo; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Kenneth P Cantor; Nathaniel Rothman; Debra T Silverman; Stephen M Hewitt; Lee E Moore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-03       Impact factor: 4.254

Review 4.  Molecular epidemiology in environmental health: the potential of tumor suppressor gene p53 as a biomarker.

Authors:  J C Semenza; L H Weasel
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

5.  Cigarette smoking and p53 mutations in lung cancer and bladder cancer.

Authors:  K Husgafvel-Pursiainen; A Kannio
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

Review 6.  Tobacco and cancer: epidemiology and the laboratory.

Authors:  P Vineis; N Caporaso
Journal:  Environ Health Perspect       Date:  1995-02       Impact factor: 9.031

7.  Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer.

Authors:  Z F Zhang; Z S Zeng; A S Sarkis; D S Klimstra; E Charytonowicz; D Pollack; J Vena; J Guillem; J R Marshall; C Cordon-Cardo
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

8.  The relationship between smoking exposure and p53 overexpression in colorectal cancer.

Authors:  A N Freedman; A M Michalek; J R Marshall; C J Mettlin; N J Petrelli; Z F Zhang; J D Black; S Satchidanand; J E Asirwatham
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.